4-chloro-1-{[(4-chloro-2-fluorophenyl)methyl]oxy}-2-iodobenzene | 892664-11-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-chloro-1-{[(4-chloro-2-fluorophenyl)methyl]oxy}-2-iodobenzene
• 英文别名: 4-chloro-1-[(4-chloro-2-fluorophenyl)methoxy]-2-iodobenzene
• CAS: 892664-11-8
• 化学式: C₁₃H₈Cl₂FIO
• 分子量: 397.015
• InChiKey: JKCHEYOFSIRTLW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-chloro-1-{[(4-chloro-2-fluorophenyl)methyl]oxy}-2-iodobenzene 在 tris-(dibenzylideneacetone)dipalladium(0) 、 异丙基氯化镁 、 potassium carbonate 、 2-二环己膦基-2'-(N,N-二甲胺)-联苯 作用下， 以 四氢呋喃 、 乙醇 、 甲苯 为溶剂， 反应 3.0h， 生成 ethyl 6-[(5-chloro-2-{[(4-chloro-2-fluorophenyl)methyl]oxy}phenyl)methyl]-2-pyridinecarboxylate
  参考文献：
  名称：

  Selection and Development of the Manufacturing Route for EP₁ Antagonist GSK269984B

  摘要：

  A potential manufacturing route for the EP1 antagonist GSK269984B was developed. Four synthetic approaches were examined, and a successful realisation of each is presented. The rationale supporting selection of the preferred route is discussed. This route utilised a phenolic aldol reaction as the key step and relied on selective hydrogenolysis to reduce an intermediate diarylmethanol. Further optimisation of the selected route is presented, delivering GSK269984B in three stages and 46% overall yield from readily available starting materials.

  DOI：

  10.1021/op100072y
• 作为产物：
  描述：

  4-氯-2-碘苯甲醚, 在 三溴化硼 、 potassium carbonate 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 反应 1.0h， 生成 4-chloro-1-{[(4-chloro-2-fluorophenyl)methyl]oxy}-2-iodobenzene
  参考文献：
  名称：

  Selection and Development of the Manufacturing Route for EP₁ Antagonist GSK269984B

  摘要：

  A potential manufacturing route for the EP1 antagonist GSK269984B was developed. Four synthetic approaches were examined, and a successful realisation of each is presented. The rationale supporting selection of the preferred route is discussed. This route utilised a phenolic aldol reaction as the key step and relied on selective hydrogenolysis to reduce an intermediate diarylmethanol. Further optimisation of the selected route is presented, delivering GSK269984B in three stages and 46% overall yield from readily available starting materials.

  DOI：

  10.1021/op100072y

文献信息

• Mild and Selective Synthesis of an Aryl Boronic Ester by Equilibration of Mixtures of Boronic and Borinic Acid Derivatives
  作者：Vanessa F. Hawkins、Mark C. Wilkinson、Matthew Whiting

  DOI：10.1021/op800169s

  日期：2008.11.21

  of aryl Grignard reagents with 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (isopropyl pinacol borate) under noncryogenic conditions can lead to mixtures of the corresponding boronic ester along with, generally undesired, borinic acid derivatives. We have found that in certain cases gentle heating of the crude reaction mixtures leads to complete equilibration to give the borinic esters as the

  在非低温条件下用2-异丙氧基-4,4,5,5-四甲基-1,3,2-二氧杂硼烷（异丙基频哪醇硼酸酯）淬灭芳基格氏试剂会导致相应的硼酸酯与通常不希望的硼酸酯混合物，硼酸衍生物。我们发现，在某些情况下，粗制反应混合物的温和加热导致完全平衡，从而得到硼酸酯作为唯一产物，然后可以高收率分离。这种新的平衡可以减少使用低温条件或大量过量的试剂在硼酸酯合成过程中获得选择性的需要。
• Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases
  申请人：Martin Paul Giblin Gerard

  公开号：US20080249138A1

  公开（公告）日：2008-10-09

  Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein X, Y, Z, R 2a , R 2b , R 3a , R 3b , R 8 , R 9 , and R x are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

  化合物的化学式为（I）或其药学上可接受的衍生物： 其中X、Y、Z、R2a、R2b、R3a、R3b、R8、R9和Rx如规范所定义，制备这种化合物的过程，包含这种化合物的药物组合物以及在医学上使用这种化合物。
• PYRIDYL COMPOUNDS
  申请人：Giblin Gerard Martin Paul

  公开号：US20090099177A1

  公开（公告）日：2009-04-16

  Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein R 1 , and R 2 , and R 3 are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

  化合物的公式(I)或其药学上可接受的衍生物：其中R1，R2和R3如规范所定义，制备这种化合物的过程，包括这种化合物的药物组合物以及这种化合物在医学上的使用。
• Pyridine compounds for the treatment of prostaglandin mediated diseases
  申请人：Glaxo Group Limited

  公开号：US07759369B2

  公开（公告）日：2010-07-20

  Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein X, Y, Z, R2a, R2b, R3a, R3b, R8, R9, and Rx are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

  化合物的公式(I)或其药学上可接受的衍生物：其中X、Y、Z、R2a、R2b、R3a、R3b、R8、R9和Rx的定义如规范所述，制备这种化合物的过程，包括这种化合物的药物组合物以及这种化合物在医学上的用途。
• WO2007/128752
  申请人：——

  公开号：——

  公开（公告）日：——